GlassScriptPhysician profile
Charles Mt Jost
NPI 1134121874
$49,873.86
in general payments reported to CMS, 2019-2025
53 companies · $3,551 in 2025
The $3,551 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,084 · 2020: $2,712 · 2021: $6,423 · 2022: $19K · 2023: $10K · 2024: $2,604 · 2025: $3,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,130 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,600 · Consulting Fee: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,129.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,600.00 |
| Consulting Fee | $3,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $14,764.79 | 2019-2025 | Igt Devices Undivided |
| Medtronic, INC. | $11,649.95 | 2021-2025 | Hawkone, Abre, Admiral Xtreme |
| Impulse Dynamics (USA) INC. | $11,455.01 | 2019-2025 | Optimizer, Optimizer |
| Medtronic Vascular, INC. | $3,222.52 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $994.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $927.24 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $869.20 | 2019-2023 | Cardiomems, Mitraclip |
| Amgen INC. | $739.55 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $489.90 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $345.42 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.75 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $298.39 | 2019-2024 | Brilinta, Wainua, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $282.56 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $274.80 | 2022-2025 | Assure Wcd |
| Terumo Medical Corporation | $257.37 | 2020-2021 |
Show all 51 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Jost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.